Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. In 2022, we anticipate reading out interim data from our ongoing Phase 2 clinical trial of GFB-887, as well as initial data from our ongoing Phase 1 study of GFB-024.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

CannaMD

AUGUST 19, 2020

Marijuana cannabinoid, CBD. Unlike THC, CBD has a high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity. .”

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

CannaMD

NOVEMBER 6, 2019

Perhaps the commercialization of marijuana and the favorable media coverage surrounding the health effects of marijuana are fostering such a perception. Some of the more interesting data on the relationship between opioids and medical marijuana for pain management comes from the field of orthopedic surgery. million to 11.4

Marijuana 87

Marijuana Patients Clinical Trials Data 87

Veriheal

AUGUST 12, 2021

million people across the United States , report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). For example, rather than having researchers carry out a controlled investigation, each study subject provided self-reported data.

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

Cannabis Law Report

MAY 6, 2022

Since 2015, the FDA has sent warning letters to companies allegedly illegally selling unapproved cannabinoid (CBD) products. Customers’ only way to know the levels of cannabinoids and other ingredients these products contain is by reviewing labels, marketing claims, and checking certificates of analysis.

THC 52

THC CBD Media Food 52

Cannabis Law Report

DECEMBER 6, 2021

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Jeff W. Jacobs, Ph.D. as Chief Scientific Officer (CSO). Dr. Jacobs, who most recently served as CSO of Ardelyx, Inc.,

Research and Development 52

Research and Development Supply Chain Clinical Trials Medicine 52

Cannabis Law Report

SEPTEMBER 24, 2019

Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. These treatments can be prescribed only by specialist doctors in a limited number of circumstances where other medicines have failed.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 14, 2021

There are 28 million people suffering from chronic pain in the UK and this range of formulations offers pain doctors the best and most comprehensive selection of cannabinoid treatment options for their patients. Media Lindsay Wilson. media@col-care.com. Investor Lee Ann Evans. Investor Relations. 1.212.271.0915.

Extraction 52

Extraction Patients Medicine Tincture 52

The Joint Blog

JULY 25, 2020

Lately, CBD has warranted a huge share of public and media attention for its perceived benefits to health and well-being. To date, FDA has not approved a marketing application for cannabis for the treatment of any disease or condition and thus has not determined that cannabis is safe and effective for any particular disease or condition.”

CBD 33

CBD Clinical Trials Safety Media 33

Cannabis Law Report

FEBRUARY 17, 2022

The Commission requires all licensees to test Marijuana and Marijuana Products for their cannabinoid profile and contaminants of concern. All Marijuana and Marijuana Products must be tested for their Cannabinoid Profile and certain contaminants of concern, as specified by the Commission.

Marijuana 52

Marijuana Seed-To-Sale Safety Patients 52

Cannabis Law Report

OCTOBER 29, 2021

We expect to report this data as it becomes available and after submission to the FDA. social media: www.igcinc.us / www.igcpharma.com. in thousands, except share data). . . . in thousands, except loss per share and share data). . . Net loss for the three months ended September 30, 2021, was approximately $4.3

Clinical Trials 52

Clinical Trials Research and Development Data Business 52

Cannabis Law Report

JULY 23, 2019

After using Koi’s products, Thurston was given a random drug test by her employer, which came back positive for cannabinoids. She lost her job as a result. Some states require mandatory warning statements in advertisements for medical cannabis. a playground, recreation centre, library or public park.

Law 40

Law Clinical Trials CBD Edibles 40

Project CBD

FEBRUARY 28, 2023

HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Consumers spent roughly $31.3 increase in annual sales. 2 The seeds of C.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

JULY 20, 2019

In New Jersey, there are nearly 50,000 registered medical marijuana patients and only six Alternative Treatment Centers (ATCs) currently operating. Ability to provide appropriate research data. MEDIA CONTACT. By: Kristin Jordan , Senior Counsel. Kristin Jordan. Criterion 5. Patient education and counseling methods.

Law 40

Law Marijuana Education Cultivation 40

Cannabis Law Report

JANUARY 4, 2022

Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for the clinical trial evaluating Nantheia™ ATL5, an investigational drug using cannabidiol (CBD) in ANANDA’s proprietary delivery technology as an Adjunctive Treatment for Opioid Use Disorder.

Clinical Trials 52

Clinical Trials Treatment Research and Development Media 52

Veriheal

JANUARY 4, 2021

In adults with chronic pain , what are the harms of Kratom or other plant-based substances for treatment of chronic pain? In adults with chronic pain, what are the harms of cannabinoids? In adults with chronic pain, what are the benefits of Kratom or other plant-based substances for treatment of chronic pain?

Chronic Pain 104

Chronic Pain Therapy Cannabinoids Treatment 104

Cannabis Law Report

SEPTEMBER 29, 2021

ANANDA is a leading research-focused biotech company pioneering high-caliber clinical studies evaluating therapeutic targets for cannabinoids. Consistent with its strong research-based data, the company also has a growing pipeline of nutraceutical over-the-counter products. Food and Drug Administration (FDA) for this trial.

Clinical Trials 52

Clinical Trials Medicine Treatment Research and Development 52

Alchimia

JANUARY 25, 2022

At the beginning of this new year of 2022, a news story about how cannabis can help fight COVID-19 was picked up by many non-cannabis media. While this research is certainly worth celebrating, the reality behind the message can be easily misunderstood in this age of social media.

Research and Development 98

Research and Development Terpenes CBD Treatment 98

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

NOVEMBER 24, 2021

Media representations can offer insights into the nature of the discourse about new medical products and therapies and how ideas and understandings about social phenomena become constructed. At the same time, the outlook on cannabis research data is largely positive. Background. Legalisation occurred in Australia in 2016.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

AUGUST 27, 2022

In the context of increasing media scrutiny and widespread public attention on celebrities for their arrest and detention resulting from the purported use of cannabis, the question as to whether cannabis consumption should be decriminalised has once again assumed significance. Appeals to Parliament.

Consumption 98

Consumption Cultivation Research and Development Cannabis 98

SpeedWeed

JULY 19, 2021

The data contained in that report has rocked the cannabis vaping world. The data was far worse than he imagined. Phytol, according to the data in the study, appeared unsafe to inhale. Until then, there was no data comparing the toxicity of inhaled phytol versus propylene glycol (PG). Its contents floored him.

Vaping 52

Vaping Terpenes Data Research and Development 52

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

OCTOBER 12, 2021

This week, Radicle Science also marks the launch of Radicle Real World Sleep, a series of first of its kind real-world evidence (RWE) studies focused exclusively on the effectiveness of cannabinoid products on sleep. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

JUNE 4, 2021

there has never been a better time for new treatment options. Our proprietary ranking system takes into account: Social reach (social media, blogs, podcasts, publications, etc.). Through his social media outlets, podcast, blog, and interviews, Tim has educated hundreds of millions of people about psychedelics. Followers.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51

The Cannigma

JANUARY 19, 2022

The resulting prejudice can often discourage folks from seeking out medical cannabis as an option, and can even affect state legislature, forcing patients to overcome unnecessary and prohibitive obstacles in order to receive the treatment they need. EG: Definitely. Specific strain names, I learned, really mean nothing.

Patients 83

Patients Compliance Compliance Cannabis 83

SpeedWeed

DECEMBER 28, 2018

Marinol (synthetic THC) has been available by prescription since 1986, and other synthetic cannabinoid drugs are in the works, but Epidiolex is the first plant-derived pharmaceutical to reach the US market. Which Cannabis Strains Are Highest in CBD, According to Lab Data? RELATED STORY. ” Sen. Jim Dabakis (D-UT). RELATED STORY.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

Veriheal

AUGUST 14, 2020

This data indicates a bit of an increase in cannabis use among expectant mothers over the course of about 15 years. . CNN and NBC both took a single study from Nature.com that also used this data as part of a study to explore neurodevelopmental outcomes in mothers who used cannabis during pregnancy.

Data 52

Data Banking Media Policy 52